Scientific Reviews
Product Guides
Blogs
Topics
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!2025-02-06
18 Results for "
phosphorylated STAT3
" in MedChemExpress (MCE) Product Catalog:
Products (18)
18 Results for "phosphorylated STAT3" in MCE Product Catalog:
6
6 Cited Publications
Cat. No.: HY-N0201
CAS No.: 73069-13-3
Category:
Terpenoids Sesquiterpenes Astragalus caprinus L. Plants Compositae Extract Disease Research Fields Cancer
Target:
1
1 Cited Publications
Cat. No.: HY-N0732
CAS No.: 37905-08-1
Cat. No.: HY-153023
CAS No.: 2429877-78-9
PROTAC STAT3 degrader-2 is a PROTAC degrader that targets STAT3, with a DC50 value of 3.54 μM. PROTAC STAT3 degrader-2 inhibits the growth of leukemia and lymphoma cells with high levels of phosphorylated STAT3. PROTAC STAT3 degrader-2 is used in the research of acute myeloid leukemia and anaplastic large cell lymphoma .
Cat. No.: HY-P10854
CAS No.: 2415370-74-8
Target:
Research Areas:
Cat. No.: HY-123099
CAS No.: 1255516-86-9
MS-1020 is a potent and ATP-competitive JAK3 inhibitor. MS-1020 inhibits JAK3/STAT signaling and induces apoptosis. MS-1020 promotes cell death. MS-1020 decreases the expression of tyrosine phosphorylated STAT3 levels. MS-1020 has the potential for the research of cancers harboring aberrant JAK3 signaling .
Cat. No.: HY-164551
CAS No.: 1423126-69-5
YLL545 is a type of vascular endothelial growth factor receptor 2 (VEGFR2) inhibitor. YLL545 can inhibit VEGF-induced phosphorylation of VEGFR2 and the activation of downstream signaling factors (like phosphorylated STAT3 and phosphorylated ERK1/2) in human umbilical vein endothelial cells (HUVEC). YLL545 can suppress the proliferation, migration, invasion, and angiogenesis of HUVEC. YLL545 can induce apoptosis in breast cancer mice and inhibit tumor growth .
Cat. No.: HY-149257
CAS No.: 2973282-50-5
HAT-SIL-TG-1&AT is a Janus tyrosine kinase (JAK) inhibitor with antitumor effects. HAT-SIL-TG-1&AT is the hypoxia-activated prodrug, witch inhibits JAK-STAT signaling in tumor tissue. And HAT-SIL-TG-1&AT inhibits HEL cells proliferation and downregulated phosphorylated STAT3/5 under hypoxic conditions .
Cat. No.: HY-N0201R
CAS No.: 73069-13-3
Cat. No.: HY-N16557
CAS No.: 77398-92-6
Category:
Cat. No.: HY-N0732R
CAS No.: 37905-08-1
Cat. No.: HY-115438
CAS No.: 1005144-85-3
AUH-6-96 is a JAK/STAT signaling inhibitor. AUH-6-96 reduces Unpaired-induced transcriptional activity in Drosophila cells and blocks tyrosine phosphorylation of STAT92E. AUH-6-96 blocks both constitutive and IL-6-induced phosphorylation of STAT3. AUH-6-96 decreases the level of tyrosine-phosphorylated JAK3. AUH-6-96 induces cancer cell Apoptosis by downregulating the expression of anti-apoptotic genes downstream of STAT3. AUH-6-96 selectively reduces the viability of cancer cells with abnormal JAK/STAT signaling pathway. AUH-6-96 is applicable to related research on Hodgkin's lymphoma, breast cancer, and prostate cancer .
Cat. No.: HY-P86737
Synonyms: STAT3(phospho Y705); p-STAT3(phospho Y705); phospho-STAT3(pTyr705); STAT3(phospho-Tyr705); p-STAT3(Tyr705); phosphorylated STAT3(pTyr705); p-STAT3; Acute Phase Response Factor; APRF; DNA binding protein APRF; FLJ20882; MGC16063; Signal Transductor and Activator of Transcription 3; STAT 3; STAT3_HUMAN.
Cat. No.: HY-P86737A
Synonyms: STAT3(phospho Y705); p-STAT3(phospho Y705); phospho-STAT3(pTyr705); STAT3(phospho-Tyr705); p-STAT3(Tyr705); phosphorylated STAT3(pTyr705); p-STAT3; Acute Phase Response Factor; APRF; DNA binding protein APRF; FLJ20882; MGC16063; Signal Transductor and Activator of Transcription 3; STAT 3; STAT3_HUMAN.
Cat. No.: HY-206870
CAS No.: 3104965-33-2
Target:
Research Areas:
BP79 is a potent TSLP receptor inhibitor. BP79 disrupts TSLP-mediated ternary complex formation, blocks TSLPR-IL7Rα co-localization, binds and stabilizes TSLPR, and inhibits phosphorylated STAT3/6. BP79 suppresses immune cell infiltration, secretion of IL-13, IL-4. BP79 can be used for the research of inflammation diseases, such as atopic dermatitis, allergic asthma, and allergic rhinitis .
Cat. No.: HY-187731
CAS No.: 685141-23-5
BXL0124 is an orally effective CD44 inhibitor and Notch signaling pathway inhibitor. BXL0124 has a vitamin D receptor-dependent mechanism and can downregulate the expression of CD44, Notch1/2/3, HES1, OCT4, LAMA5, JAG1, JAG2, NF-κB and DLL1. BXL0124 inhibits c-Myc expression and the levels of phosphorylated ERK, AKT, ErbB2, reduces the level of activated Notch1 receptor and its nuclear localization, decreases the mRNA and protein levels of Jagged-1 and Jagged-2, and inhibits the STAT3 signaling pathway by reducing the formation of the CD44-STAT3-JAK2 complex, while also inhibiting the transcriptional activity of the CD44 promoter in a p53-dependent manner. BXL0124 can induce myoepithelial differentiation and inhibit the self-renewal of cancer stem cell-like cells, cancer cell proliferation, invasion, and growth. BXL0124 can be used in research related to triple-negative breast cancer, basal-like breast cancer, ErbB2-overexpressing mammary tumorigenesis, and breast cancer .
Cat. No.: HY-115541
CAS No.: 1877286-69-5
Research Areas:
BRD4-IN-41 is a BRD4 inhibitor with an IC50 of 34 nM. BRD4-IN-41 also inhibits JAK2, FLT3, RET, ROS1, NTRK3, PDGFRb, and FGFR1 kinases with IC50 values ranging from 0.9 nM to 43 nM. BRD4-IN-41 inhibits acetyl-lysine binding site of BRD4, downregulates c-MYC, reduces phosphorylated STAT3 levels, induces G1 cell cycle arrest and apoptosis, thereby inhibiting cancer cells growth. BRD4-IN-41 can be used for the research of cancer, such as multiple myeloma and acute myeloid leukemia .
Cat. No.: HY-L008
747 compounds
The Janus kinase (JAK)/signal transducer and activator of transcription (STAT) pathway is central to signaling by cytokine receptors, a superfamily of more than 30 transmembrane proteins that recognize specific cytokines, and is critical in blood formation and immune response. Canonical JAK/STAT signaling begins with the association of cytokines and their corresponding transmembrane receptors. Activated JAKs then phosphorylate latent STAT monomers, leading to dimerization, nuclear translocation, and DNA binding. In mammals, there are four JAKs (JAK1, JAK2, JAK3, TYK2) and seven STATs (STAT1, STAT2, STAT3, STAT4, STAT5a, STAT5b, STAT6). Since the JAK/STAT pathway plays a major role in many fundamental processes, such as apoptosis and inflammation, dysfunctional proteins in the pathway may lead to a number of diseases. For example, alterations in JAK/STAT signalling can result in cancer and diseases affecting the immune system, such as severe combined immunodeficiency disorder (SCID).
MCE provides 747 compounds that can be used in the study of the JAK/STAT signaling pathway and related diseases.
- 1
-
-
Protocols
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!A suitable model is crucial in drug screening experiments. Organs can mimic the three-dimensional functional structure of internal organs, have similar spatial organization to corresponding organs, maintain some key characteristics, and reproduce some physiological functions. They are widely used for modeling and personalized drug screening physiological functions.2025-02-06
